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ABSTRACT
CDCP1, a transmembrane noncatalytic receptor, the expression of which has 
been associated with a poor prognosis in certain epithelial cancers, was found to 
be expressed in highly aggressive triple-negative breast cancer (TNBC) cell models, 
in which it promoted aggressive activities—ie, migration, invasion, anchorage-
independent tumor growth, and the formation of vascular-like structures in vitro. 
By immunohistochemical (IHC) analysis of 100 human TNBC specimens, CDCP1 was 
overexpressed in 57% of samples, 38% of which exhibited a gain in CDCP1 copy 
number by fluorescence in situ hybridization (FISH). CDCP1 positivity was significantly 
associated between FISH and IHC. CDCP1 expression and gains in CDCP1 copy number 
synergized with nodal (N) status in determining disease-free and distant disease-free 
survival. The hazard ratios (HRs) of the synergies between CDCP1 positivity by IHC 
and FISH and lymph node positivity in predicting relapse did not differ significantly, 
indicating that CDCP1 overexpression in human primary TNBCs, regardless of being 
driven by gains in CDCP1, is for a critical factor in the progression of N-positive 
TNBCs. Thus, CDCP1 is a novel marker of the most aggressive N-positive TNBCs and 
a potential therapeutic target.
INTRODUCTION
Triple-negative breast cancers (TNBCs) are highly 
aggressive, with early recurrence and leading to high 
mortality rates within the first several years postdiagnosis 
[1, 2]. Molecular profiling of TNBC specimens in the last 
decade has demonstrated the heterogeneity of this disease 
and has led to the identification of many TNBC subtypes 
[3–6], implicating several molecules as drivers of each 
subclass and thus as targets for therapy [4, 6]. However, 
none of these molecular classifications has significantly 
improved the clinical management of TNBC, with the 
exception of androgen receptor-positive [7] and BRCA-
1-deficient TNBC, for which existing therapies are 
promising [8]. Thus, the identification of specific markers 
of the aggressiveness of TNBCs that can be targeted for 
therapy remains a challenge.
CDCP1 is a transmembrane, noncatalytic receptor 
that was discovered by Scherl-Mostageer [9] and later 
isolated using an approach that was designed to identify 
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proteins that were involved in metastasis [10]. Its 
expression is associated with the loss of anchorage in 
epithelial cells during mitosis under physiological and 
pathological conditions [11], rendering tumor cells resistant 
to anoikis [12]. High membrane CDCP1 levels have been 
associated with a poor prognosis in epithelial tumors, 
such as lung, pancreatic, colorectal, renal, and ovarian 
carcinomas [13–17], but are linked to favorable prognoses 
in endometrial [18] and esophageal [19] carcinomas. 
CDCP1 mRNA and protein have been reported to be 
overexpressed in large cohorts of primary breast tumors 
and increase further in metastases [20]. Recently, CDCP1 
mRNA levels were found to rise in TNBCs and the 
mechanism by which CDCP1 effects aggressiveness has 
been suggested in cellular models [21, 22]. 
In this study, by stimulating TNBC cells with 
postsurgery wound-healing fluids (WHFs) from 
breast cancer patients to mimic a protumorigenic 
microenvironment, we identified CDCP1 as the only 
membrane receptor that was significantly upregulated. 
CDCP1 expression confers features of aggressiveness 
in TNBC cell lines and is significantly associated with 
shorter disease-free survival (DFS) and distant DFS 
(DDFS) in human primary TNBCs.
RESULTS
A protumorigenic microenvironment 
significantly upregulates CDCP1 mRNA and 
protein in TNBC cell models
The postsurgery wound-healing process can have 
protumor activity due to the enrichment in small molecules 
[23] that are needed for healing and can influence tumor 
cell survival and progression ([24] and references 
therein). Thus, we used postsurgery wound-healing fluids 
(WHFs) from breast cancer patients (Supplementary 
Table S1) to identify membrane surface molecules 
that were upregulated by the healing protumorigenic 
microenvironment and possibly involved in the 
progression of TNBC, rendering them therapeutic targets.
Five TNBC cell lines—MDA-MB-231, BT-549, and 
MDA-MB-157 (classified molecularly as mesenchymal-
like) and MDA-MB-468 and SUM149 (considered to be 
basal-like [4])—were starved, treated with pooled WHFs 
for 48 h or left untreated, and profiled using the Illumina 
platform. The experimental design comprised a training set 
and subsequent validation of an independent set of cells that 
were treated with WHFs or not (see Materials and Methods). 
Enrichment analysis according to WHF treatment identified 
several gene sets differentially and significantly enriched in 
the WHF-treated cells characterized by over expression of 
genes related to response to wound, second messenger- and G 
protein-mediated-signaling, cytokine activity and locomotory 
characteristics. (Figure 1), supporting the appropriateness 
of our approach in identifying mediators of TNBC 
aggressiveness. To identify plasma membrane receptors 
that were upregulated in TNBC models that correlated 
with TNBC aggressiveness and were potential therapeutic 
targets, we focused on molecules that resided on the cell 
membrane surface (see Materials and Methods). Based on 
a false discovery rate (FDR) < 0.1 and a fold-change >2, 
by class comparison analysis of all cell lines, CDCP1 
was the only gene that increased significantly after WHF 
stimulation, with a geometric mean fold-change in mRNA 
of 4.17 (0.0068) and 3.38 (p = 0.0077) in the training and 
validation sets, respectively. To confirm this rise in CDCP1 
mRNA, CDCP1 transcripts were amplified by TaqMan 
assay. As shown in Table 1, CDCP1 mRNA was significantly 
upregulated after WHF treatment with both probes.
We then performed western blot to determine 
whether the elevation in CDCP1 mRNA was mirrored 
by greater CDCP1 expression, detecting the 135-kD full-
length and 70-kD cleaved membrane-bound forms—which 
coexist in human tumors [25]—in 6 of the 7 TNBC cell 
lines, independent of WHF treatment (Figure 2A). On WHF 
stimulation using the same treatment schedule as in the 
gene expression profiling experiment, full-length CDCP1 
rose in all cell lines except MDA-MB-468 and MDA-
MB-157, the latter of which did not express CDCP1 at 
baseline or under WHF stimulation conditions (Figure 2A, 
2B and Table 1). No differences were noted in the induction 
of CDCP1 between the mesenchymal-like and basal-like 
subtypes (Figure 2A, 2B). The 70-kD form of CDCP1 
increased only on WHF treatment in the SUM149 and 
SUM159 cell lines (Supplementary Figure S1).
CDCP1 promotes features of aggressiveness in 
TNBC cell lines 
To determine whether CDCP1 has prometastatic 
activity, as suggested for certain human cancer histotypes 
[13–17], we analyzed the in vitro migration, invasion, 
and proliferation of 2 TNBC cell lines (BT-549 and 
MDA-MB-231) that highly express CDCP1 (Figure 2A), 
migrate, and invade, after silencing CDCP1. In both lines, 
the efficiency of CDCP1 knockdown exceeded 60% 
for both forms (Figure 3A), and consequently, CDCP1 
activation was reduced. Moreover, Src and PKCδ, 
mediators of CDCP1 signaling [26], underwent less 
phosphorylation only in MDA-MB-231 cells (Figure 3B). 
Knockdown of CDCP1 inhibited migration by 84% 
in MDA-MB-231 cells (p = 0.0196) and by 76% in the 
BT-549 line (p = 0.0465) (Figure 4A, 4B). Similarly, 
depletion of CDCP1 impeded the invasion of both cell 
lines (Figure 4C, 4D), declining by 54% in MDA-MB-231 
cells (p = 0.0173) and 56% in BT-549 (p = 0.0179) cells. 
CDCP1 knockdown did not alter the growth of MDA-
MB-231 and BT-549 cells considerably in 2D cultures 
(Figure 5A), while the decrease in growth in 3D cultures 
was significant in BT549 cells (Figure 5B). 
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We then examined whether CDCP1 affects the 
ability of TNBC cells to form vascular-like structures 
in vitro—another feature of aggressiveness that we 
recently reported in TNBC cell lines and in human 
TNBC specimens [27]—compared with other breast 
cancer subtypes. Silencing of CDCP1 in MDA-MB-231 
cells abrogated their ability to form completely closed 
loops (Figure 5C), suggesting that CDCP1 mediates the 
acquisition of vasculogenic-like networks.
Human TNBCs express CDCP1
We analyzed the expression of CDCP1 in a cohort 
of 100 human primary TNBC specimens. Of these patients 
(median age, 53 years; range 26–84 years), 42.0% was 
node (N)-positive and 58.6% of tumors were stage T1. 
As expected for TNBCs, the tumors were primarily grade 
III (85.7%) and highly necrotic (80.4%). Multifocality 
was present in 22.6% of cases, and 36.8% of patients had 
ductal carcinoma in situ (DCIS). 
Formalin-fixed, paraffin-embedded (FFPE) human 
TNBC sections were analyzed by immunohistochemistry 
(IHC) with an antibody against CDCP1. Tumors were 
considered positive when ≥ 10% of tumor cells showed 
membrane reactivity (Figure 6A) (mean CDCP1-
positive tumor cells/section = 52%, range 10% to 
100%); 57% (57/100) of cases were CDCP1-positive, 
63% (36/57) of which expressed CDCP1 in ≥ 50% of 
tumor cells (Figure 6B).
CDCP1 status in 75 of 100 available TNBC 
specimens was analyzed by fluorescence in situ 
hybridization (FISH) using a pool of 3 bacterial artificial 
chromosome (BAC) clones (BAC 2311L2, BAC 
265303, and BAC 3050I8) that encompassed CDCP1 
at chromosome 3p21.31 (Figure 7A and Supplementary 
Figure S2). By FISH analysis, we identified 4 genetic 
categories: 1) disomic, with 2 copies of CDCP1 and a 
centromere (CDCP1 < 3, CEP3 < 3) (50/75, 67%); 2) 
amplified (CDCP1 ≥ 3, CEP3 < 3 in at least 10% of 
tumor cells) (4/75, 5%); 3) polysomic (CDCP1 ≥ 3, 
CEP3 ≥ 3 in at least 40% of tumor cells) (15/75, 20%); 
and 4) CDCP1 deleted with respect to its centromere 
(CDCP1 < 3 CEP3 ≥ 3) (6/75, 8%). Figure 7B shows 
representative FISH and IHC images of CDCP1 in the 
same cases. Polysomy of CDCP1 was not a random 
event that was driven by generalized polysomy, as 
demonstrated by FISH analysis of all CDCP1-positive 
cases using a centromeric probe for chromosome 2 (data 
Figure 1: Expression of gene pathways by treatment with WHFs. Enrichment Map of pathways (Gene Ontology Biological 
Processes) significantly enriched (negative enrichment, blue; positive enrichment, red) (FDR < 0.2) in WHF-treated  compared to untreated 
TNBC cell lines  by GSEA analysis.
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not shown). CDCP1 amplification and polysomy were 
considered FISH-positive for gene acquisition, while the 
other two categories were considered FISH-negative for 
gene gain.
The FISH and IHC results were significantly 
associated—among the 19 positive cases by FISH, 
17 (89.5%) were CDCP1-positive by IHC, whereas 
28 (50.0%) of the 56 FISH-negative cases were CDCP1-
positive by IHC (p = 0.003). Thus, a gain in CDCP1 
appeared to drive CDCP1 overexpression in 38% 
of CDCP1 IHC-positive TNBCs (17/45 cases). The 
percentage of cells that were positive for CDCP1 by IHC 
correlated with the percentage of cells that harbored more 
than 3 CDCP1 signals per cell (r = 0.6121; p < 0.0001; 
Figure 7C). CDCP1-positive cases by IHC or FISH 
did not differ significantly with regard to the variables 
in Table 2 compared with their CDCP1-negative 
counterparts. 
Figure 2: Regulation of CDCP1 expression by WHF in TNBC cell lines. (A) The TNBC cell lines MDA-MB-231, BT-549, 
SUM149, SUM159, MDA-MB-157, HCC1937 and MDA-MB-468, considered basal-like (B) or mesenchymal-like (M) per Lehmann 
classification (4), were starved (0% FBS) for 24 h, stimulated for 48 h with a WHF pool, and processed for western blot analysis of CDCP1 
(the full-length 135-kD and 70-kD forms) using polyclonal anti-CDCP1. Monoclonal anti-actin was used as a loading control. The results 
are representative of 3 independent experiments. (B) The graph shows the fold-increase ± standard error of the mean (SEM) in full-length 
CDCP1 on WHF stimulation for each cell line in 3 western blot experiments, evaluated by densitometry and normalized to actin levels.
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Overexpression of CDCP1 defines a subset of 
human TNBC cases with a poorer prognosis
Based on permutation accuracy variable importance 
values, as estimated using random survival forests [28], 
for 75 TNBC cases for which IHC and FISH data were 
available, we identified CDCP1 expression and CDCP1 
positivity by FISH as prognostic factors of DFS and 
DDFS, with age, nodal involvement, tumor size, DCIS, 
and Ki-67 expression (Table 3). By multivariate Cox 
survival analysis using the prognostic covariates above, 
we observed synergistic interactions between CDCP1 
status by IHC and N status (Table 4, Figure 8A, 8B) and 
between CDCP1 status by FISH and N status (Table 4, 
Figure 8C, 8D) with regard to DFS and DDFS. 
The probability of developing distant metastases 
at 5 years of follow-up in the N-positive subgroup was 
69% for CDCP1 IHC-positive patients and 11% in CDCP1 
IHC-negative patients (p = 0.0246), whereas in N-negative 
patients, the likelihood was 11% and 20%, respectively 
(p = 0.450) (Figure 8B). Similarly, the probability of 
developing distant metastases at 5 years in the N-positive 
subgroup was 88% for CDCP1 FISH-positive cases versus 
35% for negative patients (p = 0.004) but 14% and 16% in 
Table 1: CDCP1 mRNA and protein increase upon 48 h of WHF treatment
TNBC
 cell line
Gene expression 
by microarray 
Log fold-change 
in CDCP1 gene 
expressiona
Gene expression by RT-qPCR
∆∆Ct (CDCP1 in WHF-treated and untreated cellsb
Fold-change in 
CDCP1 protein 
expressionc (mean ± 
SEMd)
Te Ve
Hs01080405_m1 Hs01080410_m1
T V T V
MDA-MB-231 4.13 3.79 1.32 2.61 1.32 2.66 1.29 (± 0.09)
BT549 3.20 1.9 2.81 2.11 4.18 2.86 1.25 (± 0.08)
SUM 149 2.10 2.64 2.37 1.08 1.4 −0.26 3.60 (± 1.42)
SUM 159 naf na na na na na 2.65 (± 1.19)
HCC1937 na na na na na na 1.61 (± 0.53)
MDA-MB-157 0.62 0.395 na na na na ndg
MDA-MB-468 0.12 0.066 2.2 2.14 2.22 1.94 0.81 (± 0.24)
Geometric Mean
(p value)
4.17
(0.0068)
3.38 
(0.0077)
4.51
(0.0061)
3.96
(0.0086)
4.86
(0.042)
3.34
(0.086)
Average protein 
fold change 
(p value)
1.87
(0.0696h)
aFold-change was calcula\ted in the training and validating sets between the normalized gene expression levels of CDCP1 in 
TNBC cell lines treated with WHFs for 48 h versus untreated. 
bCDCP1 mRNA levels were analyzed using the “best covering” probe Hs01080405_m1 and the probe Hs01080410_m1, as 
indicated by Thermo Fisher Scientific.
cFold-change in CDCP1 protein was calculated based on relative quantification of western blot signals of full-length CDCP1 
normalized to corresponding actin signals in TNBC cell lines treated with WHFs for 48 h versus untreated.
dMean ± standard error of the mean in at least 3 independent experiments.
eT, training set; V, validation set.
fna, not available.
gnd, not detectable.
hStudent t-test of normalized fold-change of CDCP1 protein expression in each cell lines.
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N-negative/CDCP1 FISH-negative and -positive patients, 
respectively (p = 0.935) (Figure 8D). The hazard ratios 
(HRs) of the synergistic interaction of CDCP1 IHC and 
FISH positivity with N positivity in predicting disease 
relapse did not differ significantly (p = 0.9478 for DFS 
and p = 0.7115 for DDFS). 
DISCUSSION
We have identified CDCP1 as a valuable marker 
of TNBC aggressiveness, implicating it as a novel 
potential therapeutic target, favored by its transmembrane 
localization, which renders it easily accessible by drugs. 
Our study demonstrates that the transmembrane receptor 
CDCP1 is overexpressed in ~60% of human primary 
TNBCs, 38% of which exhibit a gain in CDCP1 copy 
number by FISH analysis, and that CDCP1 overexpression 
is linked to shorter DFS and DDFS in TNBC.
The rise in CDCP1 mRNA and protein levels in 
TNBC cell lines on treatment with postsurgery WHFs, 
which mimic a protumor microenvironment, implicates 
CDCP1 in driving the aggressiveness of this tumor 
subtype. Despite mRNA and protein levels increasing in 
response to WHF, the extent to which they did so differed, 
possibly due to post-transcriptional mechanisms that 
regulate CDCP1 expression [29, 30] or the localization of 
CDCP1 to poorly soluble cell membrane compartments 
[31]. These mechanisms might also differentially affect 
CDCP1 levels between cell lines. Unlike the 135-kD 
CDCP1 specie, no increase in the 70-kD membrane-bound 
form was observed in most cell lines, suggesting that the 
WHF primarily regulates the full-length form, likely 
through its neosynthesis. In BT-549 and HCC1937 cells, 
in which the 70-kD form was downregulated only slightly 
after WHF treatment, the increase in the full-length form 
was nonetheless greater than the reduction in the 70-kD 
form, suggesting that the higher levels of full-length 
CDCP1 do not account for the reduction in its cleavage. 
As reported for the MDA-MB-231, T47D, and 
MDA-MB-468 breast cancer cell lines [32, 21], CDCP1 
expression and their migration and invasion in vitro were 
significantly associated. Moreover, CDCP1 promoted the 
Figure 3: Effect of silencing CDCP1 on signaling mediators. (A) MDA-MB-231 and BT-549 cells were transfected with a pool 
of 4 oligonucleotides (100 nM) that bind and degrade CDCP1 mRNA (see Materials and Methods for sequences) or with the appropriate 
negative control siRNAs. Cells were harvested at 48 h post-transfection, and CDCP1 expression was verified by western blot. Monoclonal 
anti-actin was used as a loading control. The knockdown efficiency was ≥ 60% for both CDCP1 forms. (B) CDCP1 siRNA-treated and 
control-treated MDA-MB-231 and BT-549 cells were analyzed for activation of CDCP1, Src, and PKCδ. Monoclonal anti-actin and anti-
vinculin were used as loading controls.
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formation of vascular-like channels, a property of TNBC 
that correlates with lower DFS [27], further implicating it 
in the acquisition of a more malignant phenotype. Notably, 
CDCP1 knockdown was associated with a decrease in the 
phosphorylation of canonical molecules that read out the 
activity of CDCP1 (Src and PKCδ) [26] in MDA-MB-231 
but not BT549 cells, suggesting that CDCP1-driven 
aggressiveness in TNBC cells could also be independent 
of canonical downstream molecules.
With regard to cell proliferation, we observed a 
negligible effect of CDCP1 on adhesion-dependent cell 
growth but confirmed the correlation between CDCP1 and 
anchorage-independent growth in TNBC [21]. This effect 
might depend on CDCP1-dependent resistance to anoikis 
[12], which mediates growth in vitro in 3D cultures and 
in vivo, rather than on its involvement in proliferation. 
Accordingly, whereas a study of 25 cases of breast 
cancer specimens, including hormone receptor-positive 
and -negative cases, reported that most tumors with high 
CDCP1 mRNA levels were positive for the proliferation 
marker Ki-67 [33], we found no association between 
CDCP1 expression and proliferation rates in our tumor 
series.
Consistent with our in vitro findings, TNBC 
patients with CDCP1-positive specimens had a higher 
risk of distant relapse. The prognostic value of CDCP1 
has been reported in human cancers, wherein CDCP1 
overexpression is associated with a poor prognosis in 
certain epithelial tumors [13–17, 20], but our study is 
the first description of its clinical significance in TNBC 
patients.
Our analyses in human TNBC specimens also 
revealed an interaction between CDCP1 and nodal status, 
whereby CDCP1 expression identified cases that were at 
high risk of developing distant metastases, suggesting that 
only CDCP1-positive TNBCs among tumors that have 
Figure 4: Correlation between CDCP1 and migration and invasion in TNBC cell lines. CDCP1 siRNA-treated and control-
treated MDA-MB-231 and BT-549 cells were plated into Boyden chambers for the migration assay (A, B) and in Transwells that were 
coated with Matrigel for the invasion assay (C, D). The area occupied by migrated cells in the Transwell assay (mean ± SEM in 3 
independent experiments) was measured by digital image analysis (Image Pro-Plus 7.0 application, Media Cybernetics). *p < 0.05.
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Figure 5: CDCP1 correlation with growth of TNBC cell lines. (A) Proliferation under anchorage-dependent conditions (2D) 
of CDCP1 siRNA- and control siRNA-treated cells was evaluated by SRB (mean ± SEM in 3 independent experiments). (B) Anchorage-
independent tumor growth (3D) was performed as described in Materials and Methods on MDA-MB-231 and BT-549 cells expressing 
CDCP1 or in which CDCP1 was knocked down. Colony growth was determined by counting all colonies in each well 15 days after seeding 
at 40x magnification. (C) Tube formation assay was performed as described in Materials and Methods on MDA-MB-231 cells expressing 
CDCP1 or in which CDCP1 was knocked down. *p < 0.05; ns, not significant.
Figure 6: CDCP1 expression in human primary TNBCs. (A) FFPE TNBC sections were immunostained with polyclonal anti-
CDCP1 (Thermo Fisher Scientific), and membrane staining intensity was scored as positive or negative as described in Materials and 
Methods. Scale bar: 50 μm (insets 2×). (B) Frequency distribution of human specimens by percentage of CDCP1-positive cells.
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already disseminated at the time of surgery tend to relapse. 
The similar frequencies of CDCP1-positive cases in the 
N-positive and -negative subgroups in our series raise the 
possibility that CDCP1 expression in disseminated TNBC 
accelerates the metastatic process. In N-positive TNBCs, 
for example, CDCP1 might promote transendothelial 
migration of TNBC cells or confer properties to tumor 
cells that have disseminated that improve their survival 
in circulating blood. This hypothesis is supported by the 
ability of CDCP1 to effect resistance to anoikis [12] and 
by the association between CDCP1 expression and the 
development of distant metastases in small tumors, such 
as those in our series.
The gain in CDCP1 copy number in 38% of 
CDCP1-positive TNBC cases by FISH and the evidence 
that tumors with a high number of cells that express 
CDCP1 also bear many cells with alterations in CDCP1 
support that a genetic gain in CDCP1 in this breast 
cancer subtype is  involved in CDCP1 expression. 
Nevertheless, other mechanisms might govern CDCP1 
expression in TNBC primary tumors without such gains, 
such as those in tumor hypoxia in renal cancer cells 
[34] and hepatocellular carcinoma [35], the EGF/EGFR 
pathways in ovarian models [36], BMP4 in pancreatic 
cells [37], and unidentified molecules in the tumor 
microenvironment of primary TNBCs, as suggested by 
WHF treatment.
The absence of an association of CDCP1 
expression and copy number gains with 
clinicopathological features or the expression of a basal-
like BC marker, such as cytokeratin 5/6 [38], suggests 
that CDCP1 is already present in early-stage TNBCs, 
independent of the molecular phenotype of tumor cells. 
Because mesenchymal-like and basal-like TNBCs have 
similar outcomes [4], their aggressiveness could account 
for their commonality, including their expression of 
CDCP1.
While our findings await validation in larger 
TNBC series, our data demonstrate the value of 
CDCP1 in predicting the aggressiveness of TNBC 
tumors and identify a therapeutic target for this 
disease.
Figure 7: Genetic alterations in CDCP1 in human primary TNBCs. (A) Physical map of 3p21.31 region (spanning CDCP1), 
including genomic clones selected for FISH experiments covering the CDCP1 locus, their size in Kb, and the genes that they encompass. 
Maps are derived from University of California Santa Cruz Genome Browser (http://genome.ucsc.edu/), with adaptations. (B) Representative 
images of dual-color FISH using CDCP1/CEP3 probes on FFPE human primary TNBC specimens, showing tumor cells with: > 3 red signals 
for CEP3 and > 3 green signals for the CDCP1 locus (polysomy); < 3 signals for CEP3 and > 3 green signals for CDCP1 (amplification); 
< 3 signals for CEP3 and < 3 green signals for CDCP1 (disomy); and > 3 signals for CEP3 and < 3 green signals for the CDCP1 locus 
(deletion). (C) Correlation analysis between percentage of FISH-positive cells with percentage of IHC-positive cells (n = 75; p < 0.0001; 
Pearson r 0.6121; 95% confidence interval 0.4472 to 0.7367).
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Table 2: Clinicopathological characteristics by CDCP1-IHC and CDCP1-FISH positivity
Characteristic IHC pa FISH pa
CDCP1-neg
No./total (%)
CDCP1-pos
No./total (%)
CDCP1-neg
No./total (%)
CDCP1-pos
No./total (%)
Age ≥ 50 yr 21/30 (70.0) 26/45
(57.8)
0.3356 33/56 (58.9) 14/19
(73.7)
0.7891
N-positive 9/30 
(30.0)
22/45
(48.9)
0.1510 20/56 (35.7) 11/19
(57.9)
0.1104
Tumor size
> 2.0 cm
9/30
(30.0)
21/45
(46.7)
0.2288 20/56
(35.7)
10/19
(52.6)
0.2785
Grade III 26/30 (86.7) 39/45
(86.7)
1.0000 48/56 (85.7) 17/19
(89.5)
1.0000
Multifocality 5/30
(16.7)
14/41
(34.2)
0.1138 12/54 (22.2) 7/17
(41.2)
0.2070
DCISb 11/30 (36.7) 19/43
(44.2)
0.6305 20/55 (36.4) 10/18
(55.6)
0.1759
Necrosis 23/30 (76.7) 37/43
(86.0)
0.3595 43/55 (78.2) 17/18
(94.5)
0.1647
Ki-67-positivec 20/26 (76.9) 38/42
(90.5)
0.1646 41/49 (83.7) 17/19
(89.5)
0.7137
CK5/6-positived 21/29 (72.4) 30/43
(69.8)
1.0000 38/55 (69.1) 13/17
(76.5)
0.7618
aEvaluated by Fisher exact test.
bDCIS, ductal carcinoma in situ.
cKi-67-positive, Ki-67 > 14%. 
dCK5/6-positive, cytokeratin 5/6-positive if any cytoplasmic and/or membranous invasive carcinoma cell staining was 
observed.
Table 3: Unadjusted hazard ratios (HRs) by CDCP1 positivity and clinicopathological 
characteristics
Disease-free survival Distant disease-free survival
HR 95% CIa pb HR 95% CIa pb
CDCP1 IHC-positive 2.52 1.01–6.32 0.045 2.57 0.94–7.04 0.065
CDCP1 FISH-positive 2.95 1.33–6.53 0.008 3.40 1.44–8.04 0.005
Age ≥ 50 yr 1.05 0.46–2.38 0.906 1.01 0.42–2.44 0.981
N-positive 4.59 1.90–11.11 0.001 4.65 1.80–12.06 0.002
Tumor size > 2.0 cm 2.81 1.27–6.22 0.011 2.41 1.02–5.72 0.045
DCIS c 2.67 1.16–6.13 0.021 2.99 1.19–7.51 0.020
Ki-67-positived 0.79 0.27–2.33 0.674 0.98 0.29–3.35 0.974
aCI, confidence interval; DCIS, ductal carcinoma in situ.
bEvaluated by Fisher exact test.
cDCIS, ductal carcinoma in situ
ddKi-67-positive, Ki-67 > 14%.
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Table 4: Interaction between CDCP1-IHC or -FISH status and N status in disease-free survival 
and distant disease-free survival
Disease-free survival Distant disease-free survival
HR
(95% CI)
p 5-year
survival
HR
(95% CI)
p 5-year
survival
IHC-N- 1.00 − 0.80
(0.55–0.92)
1.00 − 0.80
(0.55–0.92)
IHC+N-
0.85
(0.19–3.72)
0.828 0.85
(0.61–0.95)
0.40
(0.07–2.27)
0.414
0.89
(0.63–0.97)
IHC-N+
1.21
(0.21–6.84)
0.829 0.74(0.29–0.93)
0.56
(0.06–5.06)
0.946
0.89
(0.43–0.98)
IHC+N+
5.25
(1.51–18.20)
0.009 0.30
(0.12–0.50)
3.32
(1.03–10.70)
0.044
0.31
(0.13–0.52)
FISH-N- 1.00 − 0.82
(0.64–0.91)
1.00 − 0.84(0.66–0.93)
FISH+N-
0.76
(0.09–6.64)
0.800 0.86(0.33–0.98)
0.69
(0.08–6.20) 0.744
0.86
(0.33–0.98)
FISH-N+
2.03
(0.64–6.51)
0.231 0.61
(0.34–0.80)
1.87
(0.53–6.59)
0.332 0.65
(0.37–0.83)
FISH+N+
8.89
(2.64–29.92)
< 0.001
0.09
(0.01–0.33)
7.18
(2.09–24.65)
0.002 0.12
(0.01–0.40)
Adjusted hazard ratios (HRs) from a Cox multivariable model (with age, tumor size, Ki-67 levels, and DCIS as additional 
covariates); significance (p) of the HRs and estimated 5-year survival are listed.
Figure 8: Prognostic value of CDCP1 in TNBC primary tumors. Association between CDCP1 IHC status in N+ and N− patients 
with DFS (A) and DDFS (B) and between CDCP1 FISH status in N+ and N− patients with DFS (C) and DDFS (D). L.R. p = p-value 
by000000000 log-rank test.
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MATERIALS AND METHODS
Cell lines, cultures, and treatments
The human breast cancer cell lines MDA-MB-231, 
BT-549, MDA-MB-157, HCC1937, MDA-MB-468 
(American Type Culture Collection), SUM149, and 
SUM159 (Asterand Bioscience, Detroit, MI) were 
authenticated using a panel of microsatellite markers. Cell 
lines were maintained at 37°C in a humidified atmosphere 
of 5% CO2 in air as follows: MDA-MB-231 and BT-549 
in RPMI 1640 (Sigma-Aldrich); MDA-MB-468 in 
Dulbecco’s modified Eagle’s medium (DMEM) (Lonza); 
MDA-MB-157 in Leibovitz (Lonza); SUM149 and 
SUM159 in DMEM F12 (Lonza) that was supplemented 
with insulin (5 µg/ml); and HCC1937 in RPMI 1640 
medium that was supplemented with 1 mM sodium 
pyruvate, 1% (v/v) nonessential amino acids, and 10 mM 
Hepes. Each medium was also supplemented with 10% 
fetal bovine serum (FBS) and 2 mM glutamine (both from 
Sigma-Aldrich). For the stimulation with WHF, cells were 
starved in serum-free medium for 24 h and then treated for 
48 h with a pool of 5 WHFs at a final concentration of 5% 
as described [24]. 
Antibodies 
In the biochemical analyses, we used rabbit 
polyclonal antibody against CDCP1 (Merck Millipore); 
rabbit polyclonal phospho-CDCP1 (Tyr734) (Cell 
Signaling); mouse monoclonal anti-Src, clone GD11 
(Merck Millipore); rabbit polyclonal phospho-Src family 
(Tyr416) (Cell Signaling); rabbit polyclonal anti-PKCδ 
(Cell Signaling); rabbit polyclonal phospho-PKCδ 
(Tyr311) (Cell Signaling); mouse monoclonal anti-
vinculin, clone hVIN-1 (Sigma); anti-rabbit or -mouse 
IgG (GE Healthcare) as the secondary antibody; and 
peroxidase-linked mouse monoclonal anti-actin (Sigma-
Aldrich). In the IHC analyses, we used CDCP1 polyclonal 
antibody PA5-17245 (Thermo Fisher Scientific). 
Western blot 
To prepare crude cell lysates, cells were processed as 
described [39]. Protein concentrations were determined by 
Coomassie Plus protein assay (Thermo Fisher Scientific). 
The samples were separated on NuPage SDS-Bis-Tris 
gels (Life Technologies) and transferred onto PVDF 
membranes (EMD Millipore). Signals were detected using 
ECL reagent (GE Healthcare). Densitometric analysis 
was performed using Quantity One 1-D (Bio-Rad), with 
CDCP1 expression normalized to that of actin.
Growth, migration, and invasion in vitro assays 
Relative 2D cell growth was measured by 
sulforhodamine B (SRB) assay [40]. Optical density was 
determined on an ELISA microplate reader (Bio-Rad 
Laboratories). Anchorage-independent tumor growth (3D) 
was assessed in cells that were suspended in complete 
medium that contained 0.2 % agar and seeded in 24-well 
plates at 2500 cells/well on a 0.5–ml base of complete 
medium that contained 0.4% agar; colony growth was 
examined by counting all colonies in each well 15 days 
after seeding at 40× magnification. 
To evaluate migration, cells were seeded in the 
top of a Boyden chamber (Sigma-Aldrich) in serum-
free medium, and medium with 10% FBS was placed in 
the well below; a Matrigel layer (Basement Membrane 
Matrix; BD Bioscience) was added for the invasion 
assay. Migration and invasion by MDA-MB-231 cells 
was determined as the area that they occupied at 12 h, 
whereas for BT-549 cells, these analyses were performed 
at 6 h. At the end of the incubation, cells in the upper 
chamber were removed with cotton swabs, and those 
that traversed the Matrigel were fixed in 100% ethanol, 
stained with SRB, and imaged on an ECLIPSE TE2000-S 
inverted microscope (Nikon Instruments). The results 
were expressed as the area that was occupied by cells on 
the bottom of the Transwell, as evaluated by digital image 
analysis using the appropriate software (Image Pro-Plus 
7.0 application, Media Cybernetics) in 3 independent 
experiments (± SEM). Differences were considered to be 
significant at p < 0.05.
In vitro tube formation assay
Cells (2 × 104) were seeded in 96-well plates that 
were precoated with Matrigel (Corning) (35 µl/well, 
diluted 1:1 in medium without FBS) and incubated for 
2–4 h at 37°C. Tube formation was detected using an 
EVOS® XL Core Cell Imaging Systems inverted light 
microscope (AMG) (10× magnification) as described [27].
Knockdown of CDCP1 by siRNA transfection
Knockdown of CDCP1 with siRNA (ON-TARGET 
plus SMART pool, GE Healthcare) was performed with 
a pool of 4 oligonucleotides that could bind and degrade 
CDCP1 mRNA and were tested for silencing efficiency 
and the presence of off-targets.
Negative control: 5′ UGGUUUACAUGUCGACU 
AAdTdT3′
CDCP1-1:5′AGGAGGAGCGGGUUGAAUAdTdT3′
CDCP1-2:5′CCACGAGAAAGCAACAUUAdTdT3′
CDCP1-3:5′CCAGAAAUGUCUCCGGCUUdTdT3′
CDCP1-4:5′GAGCAUCGGUUUAGAGCUGdTdT3′
Cells were transfected with CDCP1 siRNAs 
(100 nM) using RNAiMAX (Life Technologies) or 
with the appropriate control siRNAs (On-TARGETplus 
Non-Targeting Pool, GE Healthcare), harvested at 48 h 
posttransfection, and examined for CDCP1 expression by 
western blot. Densitometric analysis was performed using 
Quantity One 1-D (Bio-Rad), with CDCP1 expression 
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normalized to that of actin. The knockdown efficiency, 
expressed as the percentage reduction in CDCP1 
expression that was induced by CDCP1 siRNA compared 
with the control siRNA, was ≥ 80%, considering both 
CDCP1 forms. Silencing of CDCP1 in MDA-MB-231 
and BT-549 cells was stable for more than 10 days (data 
not shown).
Gene expression analysis
Total RNA was isolated from samples using 
Qiazol (Qiagen). RNA integrity and purity were assessed 
on a Bioanalyzer (Agilent) after total RNA in vitro 
amplification; the RNA was then labeled with biotin and 
analyzed on Illumina HumanHT-12 V3.0 expression 
beadchips (Illumina). This array contains over 47,000 
transcripts that are derived from the UniGene database. 
Array chips were washed per the manufacturer’s protocol, 
stained with 1 µg/ml Cy3-streptavidin (GE Healthcare), 
and scanned on an Illumina BeadArray Reader. Intensity 
values were quality-checked, and the dataset was 
normalized using the quantile algorithm and BeadStudio, 
version 3. For each gene, the detection value was set to 
p < 0.05, and 50% of missing values was the cutoff to 
filter reliable data. All microarray data are MIAME-
compliant, and the raw data were deposited into the NCBI 
Gene Expression Omnibus (GEO) database (http://www.
ncbi.nmlm.nih.gov/projects/geo/) under accession number 
GSE59614. 
Bioinformatics analysis of microarray data
WHF-treated and untreated MDA-MB-231, BT-549, 
MDA-MB-468, SUM149, and MDA-MB-157 cells were 
split into training and validation sets. The experimental 
settings were designed, considering a biological replicate of 
5 paired (treated and untreated) TNBC cell lines. The data 
were validated in an independent preparation of the 5 cell 
lines following the same experimental design. Differentially 
expressed genes were imputed by class comparison, based 
on a false discovery rate (FDR) < 0.1 and following a 
paired experimental design in the training set. 
Differentially expressed genes were then tested 
in the validation set. In this dataset, 21,192 of 47,000 
transcripts were detected, and 471 Illumina probe sets 
that corresponded to 427 unique genes were differentially 
expressed: 175 probes were upregulated in WHF-treated 
cells versus 296 in untreated cells, indicating that WHF 
modulated gene expression under our working conditions. 
Gene-set enrichment analysis was performed using GSEA 
v2.0.13 [41] on GO biological processes. GSEA was run 
using a pre-ranked gene list according to the t statistic 
obtained from differential expression analysis. Because 
we aimed to identify plasma membrane receptors that 
were upregulated in TNBC models and associated with 
TNBC aggressiveness as potential therapeutic targets, 
our analyses were restricted to 796 membrane surface 
molecules that are expressed in all human tissues. This list 
was generated per Castellano et al. [42] and updated by 
a manually curated PubMed search and integration with 
HPMR [43], with the database provided by Almén [44]; 
258 of the 796 unique genes were detected in our breast 
cancer models. 
At a significance threshold of FDR < 0.1 and fold-
change > 2, only 2 gene, CDCP1, was differentially 
upregulated. CDCP1 mRNA levels were analyzed using 
the best-performing probe, ILMN_1708167, as indicated 
by Illumina Inc.; the 4.17-fold change in mRNA that 
we have reported is derived from this analysis, which 
considered all TNBC cell lines, and represents the 
geometric mean log fold-change in CDCP1 mRNA (WHF-
treated vs untreated cells). A TaqMan assay that specifically 
amplified CDCP1 transcripts (Hs01080405_m1, 
Hs01080410_m1; Thermo Fisher Scientific) was 
performed to confirm the statistically significant increase 
in CDCP1 mRNA levels that were observed in the gene 
expression analysis.
Patients and WHFs
Samples from 100 TNBC patients who were 
diagnosed between August 2002 and February 2007 
in our institute (Fondazione IRCCS Istituto Nazionale 
dei Tumori) were selected, based on IHC criteria (<1% 
of cells positive for estrogen receptor, progesterone 
receptor, and HER2 expression, classified as 0 or 1+) 
and availability of follow-up. Twelve WHFs from breast 
cancer patients who were diagnosed in 2010–2011 and 
did not undergo neoadjuvant therapy, without a high 
glycemic index (> 110 mg/dl), were collected from 
the first clearing of surgical closed-type breast drains 
(no abdomen or armpit) under suction during the 24 h 
postsurgery. WHFs were centrifuged immediately at 
3000 g, aliquoted, and stored at −80°C. The protein 
concentration in the WHFs, as determined by Biureto 
method, ranged from 3.7 to 5.1 g/dl. WHFs were pooled, 
5 at a time in each experiment, and used at a final 
concentration of 5% in medium, wherein each WHF 
had a final concentration 1%, as in our previous work 
[24]. WHFs in medium were passed through a 0.22–µm 
syringe PVDF filter (Merck-Millipore) before cell 
stimulation. 
Supplementary Table S1 lists the pathobiological 
characteristics of the patients from which the WHFs 
were derived. All patients gave written consent for use 
of their biological materials for future investigations 
and research purposes, and the study did not require 
further institutional approval from the ethics committee. 
All data were analyzed anonymously, and all 
experiments complied with the Declaration of Helsinki. 
The median follow-up of the cohort of 100 patients was 
5.4 years. 
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Immunohistochemistry
Expression of CDCP1 was analyzed by IHC on 
consecutive 2-µm formalin-fixed, paraffin-embedded 
(FFPE) tumor sections, using rabbit polyclonal anti-
CDCP1 (1:50) (PA5-17245, Thermo Fisher Scientific), 
which is directed against the C-terminus of CDCP1, 
after antigen retrieval, which as performed by heating the 
sections for 5 min at 96°C in 10 mM citrate buffer, pH 
6.0. Immunoreactions were visualized using streptavidin-
biotin-peroxidase (Dako, Agilent Technology, Santa Clara, 
CA), 3,3′-diaminobenzidine (DAB; brown signal) (Dako) 
as the chromogen, and the sections were counterstained 
with hematoxylin. Images were acquired on an ECLIPSE 
TE2000-S inverted microscope (Nikon Instruments, 
Melville, NY) at 20× and 40× magnification. 
The reactivity of anti-CDCP1 in the TNBC 
specimens was considered to be positive when ≥ 10% of 
tumor cells showed membrane staining. This cutoff was 
chosen, based on distribution analysis of the percentage 
of CDCP1-positive cells by IHC in each tumor section. 
No tumors had < 10% CDCP1-positive cells in our series, 
and cases with different percentages of CDCP1-positive 
cells were likewise distributed in a 10–100% interval. By 
explorative Kaplan-Meyer analysis of DFS in our cases—
stratified as negative, ≥ 10% and < 50%, or ≥ 50% for 
CDCP1 expression, both CDCP1-positive groups had a 
worse and superimposable DFS compared with CDCP1-
negative cases (data not shown). 
Fluorescence in situ hybridization (FISH) 
For FISH studies, 3 bacterial artificial chromosome 
(BAC) clones (BAC 2311L2, spanning only CDCP1; 
and BAC 265303 and BAC 3050I8, covering the CDCP1 
region and CLEC3B and TMEM158 on 3p21.31), chosen 
from Genome Browser of the University of California of 
Santa Cruz (www.genome.uscs.edu), were used. Each 
clone was tested by FISH in metaphase cells to confirm 
its location on 3p21.31 and to grade their signal strength 
and specificity. A commercial probe for centromere 3, 
CEP3 (Abbott Molecular), was mixed with the BAC pool 
to better assess the presence of genetic alterations, such 
as amplification, deletion, and polysomy. To improve the 
FISH signal intensity, the mixture of BACs was used after 
verifying that the percentage of positive cells remained 
identical to that obtained using only BAC 2311L2 in a 
pilot cohort of tumors (20 TNBCs). The pooled BACs 
were labeled with Spectrum Green (Abbott Molecular, 
Illinois) using a nick-translation kit (Abbott Molecular). 
A representative example of the FISH results with 
BAC 2311L2 alone or the mixture of BACs is provided 
in Supplementary Figure S2. In light of the heterogeneity 
of TNBCs, the mean signal per tumor cell for CDCP1 and 
CEP3 was recorded for each case, as was the percentage of 
tumor cells with an alteration in gene copy number. For the 
amplified CDCP1 and polysomic CDCP1 categories, we 
used cutoffs of 10% and 40% positive cells, respectively—
the same criteria that have been used for the analysis of 
HER2 [45], EGFR [46], and MET [47], the prognostic 
values of which are associated with a genetic acquisition. 
All FISH analyses were performed on FFPE tissues in 
areas that were selected by the pathologist as CDCP1-
positive by IHC or, for IHC-negative cases, representative 
of the tumor.
Statistical analysis 
Relationships between categorical variables were 
analyzed by Fisher’s exact test. Two-tailed student’s 
t-test was used to compare mean values of 2 independent 
groups; for 2 dependent groups, the equality of means 
was examined by two-tailed paired t-test. An approach 
that was based on minimal depth variable importance, 
as estimated by random survival forests [28], was used 
to select prognostic factors of DFS and DDFS. Kaplan-
Meier survival plots and exact log-rank tests were used 
to analyze differences in DFS and DDFS between 2 or 
more tumor groups. Adjusted HRs of prognostic factors 
and their 95% confidence intervals (CIs) were estimated 
by fitting multivariable Cox survival models. Differences 
were considered to be significant at p ≤ 0.05. All analyses 
were performed using Stata 13.0 (Stata) and R 3.13.2.
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